MedTrace Logo

Atrophic Gastritis Predicts the Risk of Gastric Cancer

NCT06203327 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2042

Last updated 2024-12-30

No results posted yet for this study

Summary

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Conditions

  • Atrophic Gastritis

Interventions

OTHER

Esophagogastroscopy (OLGA 0-Ⅰ)

Surveillance endoscopies at years 3-5.

OTHER

Esophagogastroscopy (OLGA II)

Surveillance endoscopies at years 2-3.

OTHER

Esophagogastroscopy (OLGA III-IV)

Surveillance endoscopies every year.

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2034-12-31
Completion
2034-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203327 on ClinicalTrials.gov